Thoratec Corporation (THOR) Earns Coverage Optimism Rating of -0.18
Press coverage about Thoratec Corporation (NASDAQ:THOR) has trended somewhat negative this week, according to Accern Sentiment. The research firm identifies positive and negative news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Thoratec Corporation earned a daily sentiment score of -0.18 on Accern’s scale. Accern also gave news stories about the medical instruments supplier an impact score of 47.2833290968714 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
COPYRIGHT VIOLATION WARNING: This report was originally published by Watch List News and is the property of of Watch List News. If you are accessing this report on another website, it was copied illegally and republished in violation of U.S. and international copyright and trademark law. The original version of this report can be accessed at https://www.watchlistnews.com/thoratec-corporation-thor-earns-coverage-optimism-rating-of-0-18/1705503.html.
About Thoratec Corporation
Thoratec Corporation develops, manufactures and markets medical devices used for mechanical circulatory support for the treatment of heart failure patients. The Company’s products include ventricular assist devices (VADs), such as HeartMate II Left Ventricular Assist System (HeartMate II), HeartMate III Left Ventricular Assist System, Thoratec Paracorporeal Ventricular Assist Device (PVAD) and Thoratec Implantable Ventricular Assist Device (IVAD).
Receive News & Ratings for Thoratec Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thoratec Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.